Bedaquiline and delamanid combination for drug-resistant TB: The Lancet Infectious Diseases: February 13, 2018

Amir Shroufi discusses the early results assessing the safety and efficacy of the combination of bedaquiline and delamanid against drug-resistant tuberculosis.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Om Podcasten

Saleha Hassan, Senior Editor at The Lancet Infectious Diseases, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from polio eradication in Africa to COVID-19 vaccines in Hong Kong, the treatment of early syphilis in adults to Mpox in the UK, and more.